The Babson Diagnostics aC19G1, a SARS-CoV-2 IgG antibody test from Babson Diagnostics, Austin, Texas, has received FDA emergency use authorization (EUA). The aC19G1 is a covid-19 serology test that enables the qualitative detection of IgG antibodies to SARS-CoV-2 with 100% sensitivity and 100% specificity. The test is designed to aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior covid-19 infection. Babson joins prestigious organizations such as New York’s Mount Sinai Laboratory and Wadsworth Center as one of only five clinical laboratories to receive an EUA for a covid-19 serology test. “Not only is serology a crucial tool for the research and understanding of covid-19, we believe it will become an essential component of ongoing preventive medicine,” says Eric Olson, Babson’s founder and CEO. “The early success of our assays, combined with our ongoing clinical studies and research partnerships, will provide pivotal insights into covid-19 immunity and help us develop future generations of tests. Today’s research and development will also inform how other testing methods such as capillary blood collection can be used to ensure convenient and decentralized access to high-quality covid-19 serology testing in the future.” For more information, visit Babson Diagnostics.